Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of TGRX-678 in relapsed/refractory accelerated-phase chronic myeloid leukemia after third-generation TKI therapy
CTR20241956Phase 2Active
- Sponsor
- Tajirui
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TGRX-678 in chronic myeloid leukemia (CML), sponsored by Tajirui. Started Jul 2024; status: active.
02
Drugs
TGRX-678
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on CTR20241956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241956.